BRCA 2 Gene Mutation clinical trials at UCLA

3 in progress, 1 open to eligible people

Showing trials for

  • CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

    open to eligible people ages 18 years and up

    This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, preliminary evidence of antitumor effect and the effect of CX-5461 on the Health-Related Quality of Life (HRQoL) will also be evaluated. The study will also evaluate the predictive value of mutational signatures and explore the significance of dynamic changes in ctDNA levels and plasma DNA methylome profiling in this study's exploratory cohort.

    Santa Monica, California and other locations

  • Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer

    Sorry, in progress, not accepting new patients

    This pilot clinical trial studies a culturally-informed counseling intervention in Latinas at high risk for hereditary breast or ovarian cancer. A culturally-informed counseling intervention may be an effective method to help people learn more about their cancer risk.

    Sylmar, California and other locations

  • BRCA Founder OutReach (BFOR) Study

    Sorry, in progress, not accepting new patients

    The purpose of this study is to learn how to provide BRCA gene testing to a larger number of people as well as to make testing part of a person's regular medical care.

    Los Angeles, California and other locations

Our lead scientists for BRCA 2 Gene Mutation research studies include .

Last updated: